Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
ACTINOBACILLUS PLEUROPNEUMONIAE SEROTYPE 2, STRAIN APP 2TR98, INACTIVATED, ACTINOBACILLUS PLEURNEUMONIAE SEROTYPE 9, STRAIN APP 9KL97, INACTIVATED, APX I TOXOID, APX II TOXOID, APX III TOXOID
ChemVet dk A/S
QI09AB07
ACTINOBACILLUS PLEUROPNEUMONIAE SEROTYPE 2, STRAIN APP 2TR98, INACTIVATED, ACTINOBACILLUS PLEURNEUMONIAE SEROTYPE 9, STRAIN APP
1-10 Per Cent
Emulsion for Injection
POM(E)
Porcine
Actinobacillus/Haemophilus vaccine
Immunological - Inactivated vaccine
Authorised
2016-10-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Suivac APP emulsion for injection for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml contains: ACTIVE SUBSTANCES: Inactivated _Actinobacillus pleuropneumoniae, _serotype 2, strain _App2TR98_ 1.0 - 10.0 U* Inactivated _Actinobacillus pleuropneumoniae, _serotype 9, strain _App9KL97_ 1.0 - 10.0 U* expressing APXI toxoid (from App 9) 1.0 - 10.0 U* expressing APXII toxoid (from App 2 and 9) 1.0 - 10.0 U* expressing APXIII toxoid (from App 2) 1.0 - 10.0 U* *One unit (1 U) corresponds to the total titrated amount of antibodies detected with ELISA in serum from vaccinated mice. ADJUVANTS: Emulsigen 0.36 ml, Saponin (extract from Quillaja Saponaria Molina) 0.10 mg. EXCIPIENTS: Thiomersal 0.10 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Emulsion for injection for pigs. White or yellowish-white liquid. By leaving to stand still an easily suspended sediment may be formed. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs (piglets, sows and gilts) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of pigs from six weeks of age for the reduction of mortality, clinical symptoms and lung lesions caused by _Actinobacillus pleuropneumoniae _serotypes 2 and 9 infections. Onset of immunity: 3 weeks after the primary vaccination. Duration of immunity: 15 weeks after the primary vaccination (based on serological data). 4.3 CONTRAINDICATIONS None. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 14/10/2016_ _CRN 7023670_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No information is available on the efficacy of the vaccine in animals with maternally d Lugege kogu dokumenti